Mineralocorticoid Antagonism and Diabetic Kidney DiseaseYuliya Lytvyn, David Z.I. Cherney, Daniël H. van Raalte et al.|Current Diabetes Reports|2019Cited by 49
Sodium glucose cotransporter (SGLT)‐2 inhibitors: Do we need them for glucose‐lowering, for cardiorenal protection or both?Rosalie A. Scholtes, Daniël H. van Raalte, Petter Bjornstad et al.|Diabetes Obesity and Metabolism|2019Cited by 35
Mechanistic evaluation of ertugliflozin in patients with type 2 diabetes and heart failureYuliya Lytvyn, David Z.I. Cherney, Rosalie A. Scholtes et al.|Physiological Reports|2025Cited by 5
Author response for "Sodium glucose cotransporter (SGLT)-2 inhibitors: do we need them for glucose-lowering, for cardiorenal protection or both?"Rosalie A. Scholtes, Daniël H. van Raalte, David Z.I. Cherney et al.|Unknown|2019Cited by 0